Apimeds Pharmaceuticals US, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Apimeds Pharmaceuticals US, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.78M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.66M) | Aug 19, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.66M) | Nov 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($402.4K) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($402.4K) | May 20, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($402.4K) | Aug 19, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($332.5K) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($449.4K) | Aug 19, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($449.4K) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($296.5K) | Aug 19, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($296.5K) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($296.5K) | May 20, 2025 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.84M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.66M) | Aug 19, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($364.4K) | May 20, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($300.0K) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($427.8K) | Aug 19, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($271.7K) | May 20, 2025 |